Sign up for our newsletter
And stay up to date with all the news from Ebram. Don't worry, we won't send spam
Few tests carry as much weight in a single result as blood typing. In an emergency situation, before any transfusion, this is the first piece of information a healthcare professional needs to have on hand. But what makes this test so crucial, and how did we arrive at it?
A discovery that changed medicine
In 1900, the Austrian physician and biologist Karl Landsteiner was conducting seemingly simple experiments: he mixed blood samples from different people and observed what happened. In some cases, the red blood cells clumped together, forming clots—a phenomenon that, inside a blood vessel, can be fatal. In others, the mixture was completely harmless. Based on these observations, Landsteiner classified humans into three blood groups—A, B, and O—and explained why some people died after transfusions while others did not. The rarer AB group was identified shortly thereafter by his collaborators.
Later, while in the United States, Landsteiner also discovered the Rh system, which distinguishes between Rh-positive blood—for those who have the factor—and Rh-negative blood—for those who do not. Given the significance of these contributions, he was awarded the Nobel Prize in Medicine in 1930. It is no coincidence that World Blood Donor Day is celebrated on June 14, Landsteiner’s birthday.
What Blood Type Determines and Why It Matters
Blood typing is the process of identifying an individual's blood type, primarily using the ABO system (A, B, AB, or O) and the Rh factor (positive or negative). This combination results in various possibilities and multiple combinations, and each one determines which blood types the individual’s blood is compatible with for donation and transfusion.
The logic behind this compatibility lies in the antigens present on red blood cells and the antibodies present in plasma. When the body receives red blood cells with antigens it recognizes as foreign, it triggers an immune response—known as hemolytic transfusion reactions—which can lead to the destruction of the transfused cells, seriously compromising the recipient’s health. For this reason, correctly identifying the blood type before any transfusion is not a mere bureaucratic formality: it is a matter of clinical safety.
In addition to transfusions, blood typing plays a central role in the diagnosis and management of conditions such as fetal erythroblastosis—a hemolytic disease of the newborn caused by Rh incompatibility between the mother and the fetus—and autoimmune hemolytic anemias, in which the patient’s own immune system attacks their red blood cells.
The chain that begins with a donation
For a typing result to be clinically reliable, the laboratory must have access to reliable reagents. And for those reagents to reach the laboratory, there must be blood available to process, test, and distribute—which brings us back to the voluntary act of donation.
Over the past two years, Brazil has seen a slight increase of 1.9% in the number of blood bags collected: 3,248,737 in 2023 and 3,310,025 in 2024, according to data from the Ministry of Health. According to the World Health Organization, the recommendation is that each country have a donor population ranging from 1% to 3%. Brazil falls within this range, but the Ministry of Health continues to run active outreach campaigns, as maintaining blood supplies at safe levels depends on consistent donor participation, especially during periods of higher demand, such as school vacations and the end-of-year holidays.
Each donation can save up to four lives, since the collected blood is separated into components—red blood cells, platelets, plasma, and cryoprecipitate—which are used in different treatments. The entire process takes about 40 minutes. What comes before and after, however, involves a rigorous series of laboratory tests, including, as a mandatory step, blood typing.
In Brazil, the most common blood types are O and A, which together account for approximately 87% of the population. About 85% of people are Rh-positive and 15% are Rh-negative, which makes O-negative blood—the universal donor—one of the most in-demand and frequently scarce types at blood centers.
The Ebram Immunohematology Line: precision where every result matters
Ebram supplies immunohematology reagents to blood banks and clinical laboratories throughout Brazil. In this context, where a single misidentification can cost a life, the quality of the reagents is no longer a competitive advantage but a requirement.
Ebram's immunohematology product line is organized into three product groups:
ABO system
Composed of Anti-A, Anti-B, and Anti-AB sera. The Anti-A serum identifies antigen A, the Anti-B serum identifies antigen B, and the Anti-AB serum, because it contains both antibodies, is especially useful as a control in typing and in situations where antigen expression may be weaker, such as in neonatal typing.
Rh system
Includes the Anti-D serum responsible for determining whether the blood is Rh-positive or Rh-negative, the Rh control, used to identify possible false-positive Anti-D reactions caused by autoantibodies, and the Anti-Human Serum. The latter combines antibodies against IgG and C3d, making it more sensitive in detecting a wider range of clinically significant antibodies than conventional Coombs serum.
Ebram recently expanded its product line with the launch of the Anti-IgG Coombs Test, a new reagent designed to expand the options available to blood banks and clinical laboratories. Specific for the detection of human IgG bound to red blood cells, it is used in direct and indirect Coombs tests and is indicated for the investigation of autoimmune hemolytic anemias, transfusion reactions, and hemolytic disease of the newborn. Its specificity for IgG makes it an accurate alternative in routines where this level of identification is necessary, and its addition to the Ebram portfolio reinforces the line’s mission: to provide laboratories with reagents for every stage and every need in the immunohematology routine.
Supplementary Reagents
Bovine Albumin 22% complements the product line by enhancing the sensitivity of specific antibodies in the indirect antiglobulin test, making visible reactions that would otherwise go unnoticed.
Specifications that exceed the requirements
The reagents in the Ebram line are validated and approved by blood banks throughout Brazil. The internal specifications for avidity, titration, and score exceed the minimum requirements, demonstrating a measurable commitment to the reliability of results. For example, the Anti-A serum has an avidity time of 6 seconds on A1 red blood cells, compared to the accepted limit of up to 15 seconds; and a titer of 1:512, compared to the minimum requirement of 1:256.
When every second counts and every result must be accurate, having reagents that can meet this responsibility is not just a minor detail—it is what underpins the entire safe blood therapy chain.
Visit the website and learn more about the Immunohematology Line.
You can also contact us through our service channels, staffed by experts who are ready to answer any questions you may have:
📞 Sales Department: (11) 2291-2811
✉️ Email: [email protected]
📞 Customer Service: 0800 500 2424 | [email protected]
And stay up to date with all the news from Ebram. Don't worry, we won't send spam